Want to see HK:1513 full AI Analyst Report?
1513 Stock Chart & Stats
HK$25.96
HK$0.04(0.15%)
At close: 4:00 PM EDT
HK$25.96
HK$0.04(0.15%)
Day’s Range― - ―
52-Week RangeHK$23.24 - HK$38.80
Previous CloseN/A
Volume286.26K
Average Volume (3M)553.85K
Market Cap
HK$28.62B
Enterprise ValueHK$18.05K
Total Cash (Recent Filing)HK$9.56B
Total Debt (Recent Filing)HK$2.89B
Price to Earnings (P/E)13.2
Beta0.77
Next Earnings
Oct 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.59%
Share Statistics
EPS (TTM)2.21
Shares Outstanding299,807,130
10 Day Avg. Volume697,200
30 Day Avg. Volume553,853
Financial Highlights & Ratios
PEG Ratio8.43
Price to Book (P/B)1.65
Price to Sales (P/S)1.90
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.00Price Target Upside11.71% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.41
Revenue Forecast (FY)HK$12.39B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and operating margins indicate structural cost advantages and pricing power in core products. These margins support durable earnings generation, fund R&D and product development, and help maintain return on equity (~14–15%) even if top-line growth remains muted.
Conservative LeverageLow leverage provides balance-sheet flexibility to absorb shocks, fund capex or strategic investments, and sustain distributions. Conservative capital structure reduces refinancing and interest-rate risk, supporting steady operations and optionality for long-term capital allocation decisions.
Strong Free Cash FlowRobust and growing free cash flow that approximates reported earnings indicates high earnings quality and internal funding capacity. Reliable FCF enables reinvestment, product development, and shareholder returns without heavy external financing, strengthening long-term financial resilience.
Bears Say
Multi-year Revenue DeclineA persistent top-line decline reduces scale benefits and constrains long-term growth prospects. Even with healthy margins, shrinking revenues limit absolute profit growth, squeeze future investment capacity, and make sustaining historical returns harder without clear new growth drivers.
Weak Cash Conversion Vs EBITLow operating cash conversion versus operating profit suggests working-capital or timing volatility that can make cash flow less predictable. This variability can constrain consistent reinvestment, M&A or dividend policies despite solid reported profitability, raising execution risk.
Limited Balance-Sheet CatalystsA stable asset base amid slowing revenue implies fewer organic expansion opportunities driven by balance-sheet deployment. Absent revenue reacceleration or strategic deals, the company may struggle to generate fresh upside from its existing asset footprint over the medium term.
Livzon Pharmaceutical Group News
1513 FAQ
What was Livzon Pharmaceutical Group Inc Class H’s price range in the past 12 months?
Livzon Pharmaceutical Group Inc Class H lowest stock price was HK$23.24 and its highest was HK$38.80 in the past 12 months.
What is Livzon Pharmaceutical Group Inc Class H’s market cap?
Livzon Pharmaceutical Group Inc Class H’s market cap is HK$28.62B.
When is Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date?
Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date is Oct 27, 2026 which is in 66 days.
How were Livzon Pharmaceutical Group Inc Class H’s earnings last quarter?
Livzon Pharmaceutical Group Inc Class H released its earnings results on Aug 21, 2026. The company reported HK$1.225 earnings per share for the quarter, beating the consensus estimate of HK$0.747 by HK$0.478.
Is Livzon Pharmaceutical Group Inc Class H overvalued?
According to Wall Street analysts Livzon Pharmaceutical Group Inc Class H’s price is currently Undervalued.
Does Livzon Pharmaceutical Group Inc Class H pay dividends?
Livzon Pharmaceutical Group Inc Class H pays a Annually dividend of HK$1.643 which represents an annual dividend yield of 6.59%. See more information on Livzon Pharmaceutical Group Inc Class H dividends here
What is Livzon Pharmaceutical Group Inc Class H’s EPS estimate?
Livzon Pharmaceutical Group Inc Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Livzon Pharmaceutical Group Inc Class H have?
Livzon Pharmaceutical Group Inc Class H has 299,807,130 shares outstanding.
What happened to Livzon Pharmaceutical Group Inc Class H’s price movement after its last earnings report?
Livzon Pharmaceutical Group Inc Class H reported an EPS of HK$1.225 in its last earnings report, beating expectations of HK$0.747. Following the earnings report the stock price went down -2.044%.
Which hedge fund is a major shareholder of Livzon Pharmaceutical Group Inc Class H?
Currently, no hedge funds are holding shares in HK:1513
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Livzon Pharmaceutical Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$29.00 (11.71% Upside)
HK$29.00 (11.71% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.61%
12-Months-Change
Fundamentals
Return on Equity
6.59%
Trailing 12-Months
Asset Growth
3.72%
Trailing 12-Months
Company Description
Livzon Pharmaceutical Group Inc Class H
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.
1513 Stock 12 Month Forecast
Average Price Target
HK$29.00
▲(11.71% Upside)
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―